Drug-induced nephrotoxicity in inflammatory bowel disease

Nephron Clin Pract. 2011;119(2):c89-94; discussion c96. doi: 10.1159/000326682. Epub 2011 Jun 15.


Conservative management of inflammatory bowel disease (IBD) is based on a combination of drugs, including aminosalicylates (ASAs), steroids, antibiotics, immunosuppressives and biologic agents. Although various side effects have been related to treatment regimens, drug-induced nephrotoxicity is rather uncommon. Furthermore, it is often underestimated since renal function deterioration may be attributed to the underlying disease. The nephrotoxicity of ASAs and cyclosporine A seems well established, but recent data have suggested a possible role of biologic agents such as infliximab and adalimubab in renal impairment. The aim of this review is to summarize the nephrotoxic effects of medical treatment as well as to express possible caveats in the administration of novel agents in IBD.

Publication types

  • Review

MeSH terms

  • Aminosalicylic Acids / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Cyclosporine / adverse effects
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Inflammatory Bowel Diseases / drug therapy*
  • Kidney Diseases / chemically induced*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors


  • Aminosalicylic Acids
  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Cyclosporine